Telik Inc. - 500 Beiträge pro Seite

[Kostolanys Erbe]

Telik, Inc. (Nasdaq: TELK) is a biopharmaceutical company working to discover, develop and commercialize small molecule drugs focused in cancer and diabetes. The company`s most advanced drug development programs include: TLK286, a tumor activated drug candidate currently in Phase 2 clinical trials for the treatment of chemotherapy resistant colorectal, ovarian and non-small cell lung cancers; TLK199, a candidate for the treatment of depletion of infection-fighting white blood cells that occurs as a toxic side effect of cancer therapy as well as in other blood diseases such as myelodysplastic syndrome; and a family of orally active insulin receptor activators for Type 2 diabetes. Telik`s product candidates were discovered using its proprietary technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates.

Our strategy for maximizing the commercial value of our product pipeline is to retain rights through initial clinical safety and efficacy evaluations. Once we have demonstrated clinical utility, we will evaluate a range of development and commercialization options.

In addition to its proprietary drug development programs, Telik partners with pharmaceutical and biotechnology companies to apply its TRAP technology to a variety of research programs directed at new drug development. Current partners include Sanwa Kagaku Kenkyuosho Co., Ltd. and Sankyo Company, Ltd. Telik also collaborates with leading academic institutions including the University of Arizona Cancer Center, the University of California, San Francisco and the Fox Chase Cancer Center.


Telik (Nasdaq: *!TELK!*) - BUY - Telik, based in San Francisco, CA, is a
biotechnology company with expertise in identifying and developing small
molecule drugs. The company`s core TRAP technology, a novel "low
throughput" approach for drug screening, complements traditional high
throughput methods.

Strengths:
* Strong cash position. As of the end of 2Q01, Telik had $36.2 million
in cash and equivalents. The company recently completed a secondary
offering, further strengthening its cash position. While the burn rate
will increase as the clinical development program expands, Telik has
ample cash reserves.

* Fully owned clinical and late development candidates. Telik has
complete ownership of its two most advanced candidates, TLK-286 and
TLK-199 and is conducting its own clinical trial programs for these
drugs, maximizing the value of these candidates.

* Low visibility, high potential early pipeline. TLK-286 is Telik`s only
product currently in clinical testing. However, phase I trials for
candidate TLK-199, a drug that mimics the effect of Neupogen (Amgen),
which had 2000 sales of $1.2 billion are expected to begin by year-end.
Also in preclinical development is TLK-17411, a promising treatment for
diabetes.

[Kostolanys Erbe]

evtl. Trendwende, wenn sich das Umfeld im Biotechsektor verbessert.

Kosto

Keiner eine Meinung zu Telik?

www.Telik.com